King's College London

Research portal

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies

Research output: Contribution to journalLetterpeer-review

the BADBIR Study Group

Original languageEnglish
Pages (from-to)e496-e498
JournalJournal of the European Academy of Dermatology and Venereology
Volume35
Issue number8
DOIs
Accepted/In press2021
PublishedAug 2021

Bibliographical note

Funding Information: BADBIR is coordinated by The University of Manchester, and funded by the British Association of Dermatologists (BAD). The BAD receives income from AbbVie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Samsung Bioepis, Sandoz Hexal AG and UCB Pharma for providing pharmacovigilance services. This income finances a separate contract between the BAD and The University of Manchester who coordinate BADBIR. AbbVie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Samsung Bioepis, Sandoz Hexal AG and UCB Pharma had no role in: the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Prof Christopher Griffiths and Prof Nick Reynolds are NIHR Senior Investigators. We acknowledge support from the Manchester NIHR Biomedical Research Centre, Department of Health via the NIHR BioResource Clinical Research Facility and comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust (guysbrc‐2012‐1) and the Newcastle NIHR Biomedical Research Centre. Prof Nick Reynolds is also supported by the Newcastle NIHR Medtech and In vitro diagnostic Co‐operative. The BADBIR Study Group includes Jonathan Barker; Gabrielle Belcher; Anthony Bewley; Fiona Browne; A David Burden; Ian Evans; Christopher Griffiths; Brian Kirby; C Elise Kleyn; Philip Laws; Linda Lawson; Kathleen McElhone; Teena Mackenzie; Tess McPherson; Simon Morrison; Ruth Murphy; Anthony Ormerod; Caroline Owen; Eleanor Pearson; Nick Reynolds; Josh Richards; Catherine Smith; and Richard Warren. Group Information: Funding Information: We acknowledge the enthusiastic collaboration of all of the dermatologists and specialist nurses in the U.K. and the Republic of Ireland who provided the data. The principal investigators at the participating sites at the time of data cut‐off are listed on the following website: http://www.badbir.org . The authors acknowledge the substantial contribution of the BADBIR team at The University of Manchester to the administration of the project. BADBIR acknowledges the support of the National Institute for Health Research (NIHR) through the clinical research networks and its contribution in facilitating recruitment into the registry. CEMG is supported in part by the NIHR Manchester Biomedical Research Centre. The authors are grateful to the members of the Data Monitoring Committee (DMC): Robert Chalmers, Carsten Flohr (Chair), David Prieto‐Merino, and Richard Weller; and the BADBIR Steering Committee (listed under Group Information). Funding Information: We acknowledge the enthusiastic collaboration of all of the dermatologists and specialist nurses in the U.K. and the Republic of Ireland who provided the data. The principal investigators at the participating sites at the time of data cut-off are listed on the following website: http://www.badbir.org. The authors acknowledge the substantial contribution of the BADBIR team at The University of Manchester to the administration of the project. BADBIR acknowledges the support of the National Institute for Health Research (NIHR) through the clinical research networks and its contribution in facilitating recruitment into the registry. CEMG is supported in part by the NIHR Manchester Biomedical Research Centre. The authors are grateful to the members of the Data Monitoring Committee (DMC): Robert Chalmers, Carsten Flohr (Chair), David Prieto-Merino, and Richard Weller; and?the BADBIR Steering Committee (listed under Group Information). Funding Information: KJM has received honoraria from Janssen, LEO Pharma, Lilly and Novartis. ADB consults and lectures for Abbvie, Amgen, Boehringer Ingelheim, Celgene, Janssen, Lilly, Novartis and Pfizer. JNWN has received honoraria for advisory boards and lectures at sponsored symposia together with grants for research in the past 5 years from AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, and Pfizer. CEK has received honoraria and/or research funding from AbbVie, Celgene, Galderma, GSK‐Stiefel, Janssen, Johnson & Johnson, LEO Pharma, Lilly, Novartis, Pfizer and UCB Pharma. KM has received honoraria from Lilly and UCB Pharma. CEMG has received honoraria and/or research grants from Abbvie, Actelion, Almirall, Amgen, Celgene, Galderma, LEO Pharma, GSK‐Stiefel, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals and UCB Pharma. NJR reports grants from PSORT industrial partners as listed ( http://www.psort.org.uk/ ); other research grants from GSK‐Stiefel and Novartis; and other income to Newcastle University from Almirall, Amgen, Janssen, Novartis, Sanofi Genzyme Regeneron and UCB Pharma Ltd for lectures/attendance at advisory boards. All other authors (ML; HA; MMS; ACG; ADO) declare no conflicts. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454